Reports FY24 revenue $441k, consensus $224.5k. “2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-1beta. We filed our IND application with the FDA, designed and launched the Phase 2 LOTUS trial in hidradenitis suppurativa (“HS”) and rapidly progressed its initiation, including IND activation in July and enrollment of the first patient in October. Our primary focus in 2025 is executing the LOTUS trial to release data in 2026, while exploring broader applications for AVTX-009 and announcing a second indication.”
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Walgreens downgraded, Cava Group upgraded: Wall Street’s top analyst calls
- Piper Sandler bullish on Avalo Therapeutics, initiates with an Overweight
- Avalo Therapeutics initiated with an Overweight at Piper Sandler
- Rivian downgraded, Unity upgraded: Wall Street’s top analyst calls
- Avalo Therapeutics initiated with an Outperform at Wedbush